An innovation in vaccine development has emerged from researchers at The University of Edinburgh which could well help in the fight against Malaria.
The Edinburgh based researchers have developed a synthetic vaccine that incorporates the highly variable repeat sequences of the merozoite surface protein antigen from Plasmodium falciparum.
Plasmodium falciparum is transmitted to human beings through the bite of the female Anopheles mosquito and is the most common cause of human malaria. It's extensive polymorphism nature has been a complex challenge for vaccine design, however, there is significant experimental evidence to suggest that polymorphic regions of the parasite play a role in natural immunity.
Now, however, Edinburgh's researchers have designed a novel synthetic hybrid sequence, incorporating all the known immunogenic antibody epitopes for each of the K1 and MAD20 polymorphic Block 2 regions. Pre-clinical animal trials are looking extremely promising.